Stak...thanks for the Biofrontera grant info. Posters with agendas can twist and distort the news all they want to little effect...because what's important is that Biofrontera is receiving $4 million EU = $5,293,768.24 US ($5.2 million USD) for two years of research in their "core areas":
"The research grant is aimed at supporting the discovery of innovative drug candidates for the treatment of chronic Pain and Parkinson's Disease."
Both pain and Parkinson's are huge million dollar markets for DNAP/Biofrontera...pain especially!
That's an additional $2.6 million US a year for Biofrontera...on top of DNAP's pending investment of $25 million US over the next few years. More than enough cash to bring exciting drug products to market.
Sounds like kids in a Disney park having enough money to do ALL the rides...lol!
Better yet...it sounds like dedicated research scientists getting the critical funding to explore and develop their dreams into reality...a confirmation of their important work that has the potential for humanity to lessen pain and disease.
The biggest question for any innovative "penny stock" is whether they have enough cash to survive while their "disruptive technology" becomes established with revenue-generating products...
Without a doubt...DNAP and Biofrontera are sitting cash pretty for the next few years, a very laudable position that should be encouraging for DNAP investors.
Thanks for your posts.
God Bless and take care,
Robert
News 
Market Data 
Discover 
AI
